BioRestorative Therapies Files 8-K
Ticker: BRTX · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1505497
Sentiment: neutral
Topics: 8-K, filing, disclosure
TL;DR
BRTX filed an 8-K, likely just routine updates. Keep an eye out for details.
AI Summary
BioRestorative Therapies, Inc. filed an 8-K on February 10, 2025, reporting on its current activities. The filing primarily serves as a notification of information and exhibits, with no specific material events detailed in the provided text. The company, formerly known as Stem Cell Assurance, Inc., is based in Melville, New York.
Why It Matters
This 8-K filing indicates BioRestorative Therapies, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's status.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific material events or financial disclosures that would indicate a high-risk situation.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- February 10, 2025 (date) — Date of Report
- Stem Cell Assurance, Inc. (company) — Former Company Name
- Melville, New York (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for BioRestorative Therapies, Inc.?
The filing serves as a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the company is reporting information or exhibits.
When was this 8-K report filed?
The report was filed on February 10, 2025.
What is the principal executive office address for BioRestorative Therapies, Inc.?
The address is 40 Marcus Drive, Melville, New York 11747.
Did BioRestorative Therapies, Inc. have a former name?
Yes, the company was formerly known as Stem Cell Assurance, Inc., with a name change date of November 10, 2010.
What is the SIC code for BioRestorative Therapies, Inc.?
The Standard Industrial Classification (SIC) code is 8090, categorized under SERVICES-MISC HEALTH & ALLIED SERVICES, NEC.
Filing Stats: 835 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-02-10 08:32:48
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- brt8k21025.htm (8-K) — 27KB
- ex99_1.htm (EX-99.1) — 1KB
- pm.htm (EX-99.2) — 8KB
- brtpr_1.jpg (GRAPHIC) — 1006KB
- brtpr_2.jpg (GRAPHIC) — 1198KB
- brtpr_3.jpg (GRAPHIC) — 542KB
- osr_1.jpg (GRAPHIC) — 609KB
- osr_2.jpg (GRAPHIC) — 1031KB
- osr_3.jpg (GRAPHIC) — 536KB
- osr_4.jpg (GRAPHIC) — 574KB
- osr_5.jpg (GRAPHIC) — 476KB
- osr_6.jpg (GRAPHIC) — 683KB
- osr_7.jpg (GRAPHIC) — 385KB
- osr_8.jpg (GRAPHIC) — 534KB
- osr_9.jpg (GRAPHIC) — 323KB
- osr_10.jpg (GRAPHIC) — 615KB
- osr_11.jpg (GRAPHIC) — 660KB
- osr_12.jpg (GRAPHIC) — 705KB
- osr_13.jpg (GRAPHIC) — 582KB
- osr_14.jpg (GRAPHIC) — 664KB
- osr_15.jpg (GRAPHIC) — 700KB
- osr_16.jpg (GRAPHIC) — 490KB
- osr_17.jpg (GRAPHIC) — 514KB
- osr_18.jpg (GRAPHIC) — 473KB
- osr_19.jpg (GRAPHIC) — 602KB
- osr_20.jpg (GRAPHIC) — 396KB
- 0001021771-25-000031.txt ( ) — 19853KB
- brtx-20250210.xsd (EX-101.SCH) — 4KB
- brtx-20250210_lab.xml (EX-101.LAB) — 21KB
- brtx-20250210_pre.xml (EX-101.PRE) — 16KB
- brt8k21025_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure . On February 10, 2025, BioRestorative Therapies, Inc. (the "Company") issued a press release (the "Press Release") announcing that, on February 8, 2025, Francisco Silva, the Company's Vice President of Research and Development, presented at the Orthopaedic Research Society (ORS) 2025 Annual Meeting (the "ORS Annual Meeting") in Phoenix, Arizona. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. At the ORS Annual Meeting certain presentation materials (the "Presentation Materials") were utilized by Mr. Silva. The Company intends to use the Presentation Materials from time to time on and after the date of this Current Report on Form 8-K in presentations about the Company's business. As indicated above, the Company used the Presentation Materials at the ORS Annual Meeting on February 8, 2025 and may use the Presentation Materials, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business. The information contained in the Presentation Materials is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so. The Presentation Materials are furnished as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. The Presentation Materials will also be posted on the Company's website, www.biorestorative.com , under "Sc
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated February 10, 2025, issued by BioRestorative Therapies, Inc. 99.2 Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: February 10, 2025 By: /s/ Robert Kristal Robert Kristal Chief Financial Officer